NoopeptvsSAMe

Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.

SAMe serves as the principal methyl donor in over 100 transmethylation reactions catalyzed by SAM-dependent methyltransferases. In the brain, it donates methyl groups to phosphatidylethanolamine N-methyltransferase (PEMT), converting PE to phosphatidylcholine and maintaining neuronal membrane fluidity critical for receptor function. It methylates DNA via DNMT enzymes, modulating gene expression epigenetically. SAMe is essential for catechol-O-methyltransferase (COMT) activity, which metabolizes dopamine and norepinephrine, and for phenylethanolamine N-methyltransferase (PNMT), which converts norepinephrine to epinephrine. It feeds the transsulfuration pathway, producing cysteine via cystathionine beta-synthase (CBS) and cystathionine gamma-lyase, ultimately supporting glutathione synthesis for antioxidant defense. SAMe also donates methyl groups for myelin basic protein methylation, essential for myelin sheath integrity and nerve conduction velocity.